PRT-060318 10mg 10mg | Purity Not Available
Adooq Bioscience
PRT-060318 is a novel selective inhibitor of the tyrosine kinase Syk, as an approach to HIT treatment.
More Information Supplier PagePRT-060318 is a novel selective inhibitor of the tyrosine kinase Syk, as an approach to HIT treatment.
More Information Supplier PageCIQ is a subunit-selective potentiator of NMDA receptors containing the NR2C or NR2D subunit.
More Information Supplier PageCIQ is a subunit-selective potentiator of NMDA receptors containing the NR2C or NR2D subunit.
More Information Supplier PageCIQ is a subunit-selective potentiator of NMDA receptors containing the NR2C or NR2D subunit.
More Information Supplier PageL-701324 is an orally active and long acting anticonvulsant with high affinity and selectivity for the glycine site on the NMDA receptor,
More Information Supplier PageL-701324 is an orally active and long acting anticonvulsant with high affinity and selectivity for the glycine site on the NMDA receptor,
More Information Supplier PageL-701324 is an orally active and long acting anticonvulsant with high affinity and selectivity for the glycine site on the NMDA receptor,
More Information Supplier PageAI-10-49 is a protein-protein interaction inhibitor that selectively binds to CBF??-SMMHC and disrupts its binding to RUNX1 with a FRET IC50 of 0.26 uM,
More Information Supplier PagePRT-060318 is a novel selective inhibitor of the tyrosine kinase Syk, as an approach to HIT treatment.
More Information Supplier PageGW627368 is a novel, potent and selective competitive antagonist of prostanoid EP4 receptor(Ki= 100 nM) with additional human TP receptor affinity(Ki= 150 nM).
More Information Supplier Page